05/25/22 8:30 AMNasdaq : VERU conferenceshigh shortVeru to Participate in Fireside Chat at the Jefferies Healthcare Conference on June 8, 2022Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers, today announced that the Company will participate in aRHEA-AIneutral
05/18/22 8:30 AMNasdaq : VERU managementcovid-19high shortVeru Announces Appointment of Joel Batten to Lead U.S. Infectious Disease Franchise to Focus on Hospitalized COVID-19 PatientsVeru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers, today announced the appointment of Joel Batten asRHEA-AIneutral
05/17/22 8:30 AMNasdaq : VERU conferenceshigh shortVeru to Present at the H.C. Wainwright Global Investment Conference on May 24th 2022Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers, today announced that the Company will present at theRHEA-AIneutral
05/12/22 6:30 AMNasdaq : VERU earningscovid-19high shortVeru Reports Second Quarter Fiscal 2022 Results and Progress of Sabizabulin for COVID-19 Toward a Request for Emergency Use AuthorizationIDMC Unanimously Votes to Halt the Ongoing Phase 3 Trial of Sabizabulin forRHEA-AIneutral
05/11/22 6:30 AMNasdaq : VERU clinical trialcovid-19high shortFDA States that Veru Should Submit Request for Emergency Use Authorization (EUA) Based on Positive Efficacy and Safety Data from the Phase 3 Clinical Study of Sabizabulin in Hospitalized COVID-19 PatientsTheRHEA-AIneutral
05/02/22 8:30 AMNasdaq : VERU clinical trialcovid-19high shortFDA Has Granted Veru a Pre-Emergency Use Authorization (EUA) Meeting Date for Positive Sabizabulin Phase 3 COVID-19 Study Veru Inc. (NASDAQ: VERU), a biopharmaceutical company, today announced that the FDA has granted the Company a pre-Emergency Use Authorization (EUA) meeting on May 10, 2022, for the positive Phase 3 COVID-19 study for sabizabulin. “We want to keep ourRHEA-AIneutral
04/28/22 8:30 AMNasdaq : VERU conferencesearningshigh shortVeru to Report Fiscal 2022 Second-Quarter Financial Results, Host Conference Call on May 12thVeru Inc. (NASDAQ: VERU), a biopharmaceutical company, today announced that it will report financial results for its fiscal 2022 second quarter, on Thursday, May 12, 2022, before the market opens. Veru’s management will host a conference call that sameRHEA-AIneutral
04/25/22 8:30 AMNasdaq : VERU clinical trialcovid-19high shortVeru Announces Oral Late-Breaking Presentation of Phase 2 Data of Sabizabulin for the Treatment of Hospitalized Severe COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome at the 32nd European Congress of Clinical Microbiology & Infectious DiseasesVeru Inc. (NASDAQ: VERU), a biopharmaceutical company, today announced that results from the randomized placebo-controlled Phase 2 study of daily, oral sabizabulin in patients with severe COVID-19 at high risk for acute respiratory distress syndromeRHEA-AIneutral
04/11/22 6:30 AMNasdaq : VERU clinical trialcovid-19high shortVeru’s Novel COVID-19 Drug Candidate Reduces Deaths by 55% in Hospitalized Patients in Interim Analysis of Phase 3 Study; Independent Data Monitoring Committee Halts Study Early for Overwhelming EfficacySabizabulin Treatment Showed Statistically SignificantRHEA-AIneutral
03/04/22 8:30 AMNasdaq : VERU high shortVeru Announces Acceptance of Two Abstracts for Presentation at the 39th Miami Breast Cancer ConferenceVeru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of breast and prostate cancers, today announced that two abstracts were accepted for presentation at the 39 th Miami BreastRHEA-AIneutral